GFAP and Alzheimer disease: In conclusion, in this large community-based study elevated levels of several AD blood biomarkers—particularly p-tau217, NfL, and GFAP—were associated with a faster progression from MCI to all-cause and AD dementia and with decreased MCI reversion.